Teriparatide oral - Emisphere Technologies/Novartis
Alternative Names: Parathyroid-hormone-1-34-oral; PTH-1-34-oral-Emisphere-Technologies-Novartis; PTH1-34Latest Information Update: 24 Oct 2021
At a glance
- Originator Emisphere Technologies
- Developer Novartis
- Class Diagnostic agents; Osteoporosis therapies; Peptide hormones; Skin disorder therapies
- Mechanism of Action Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Postmenopausal osteoporosis
Most Recent Events
- 08 Dec 2020 Emisphere Technologies has been acquired by Novo Nordisk
- 17 Jun 2011 Discontinued - Phase-I for Postmenopausal osteoporosis in Denmark (PO)
- 17 Jun 2011 Discontinued - Phase-I for Postmenopausal osteoporosis in Germany (PO)